Targeting the Mitotic Catastrophe Signaling Pathway in Cancer

Mediators of Inflammation

Volumn 2015, Issue , 2015, Pages

  Mc Gee, Margaret M ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BH3 PROTEIN; PROTEIN BCL 2;

ANEUPLOIDY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CANCER THERAPY; CELL CYCLE M PHASE; CELL DEATH; CELL FATE; CELL MATURATION; CELLULAR, SUBCELLULAR AND MOLECULAR BIOLOGICAL PHENOMENA AND FUNCTIONS; CENTROSOME; DNA DAMAGE; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; IN VIVO STUDY; M PHASE CELL CYCLE CHECKPOINT; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL PERMEABILITY; MITOSIS; MITOSIS INHIBITION; MITOSIS SPINDLE; MITOTIC CATASTROPHE; NEOPLASM; NONHUMAN; OLIGOMERIZATION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; DRUG EFFECTS; GENETICS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; MITOSIS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84944249316     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2015/146282     Document Type: Review

References (137)

1. D. Hanahan and R. A. Weinberg, "Hallmarks of cancer: the next generation," Cell, vol. 144, no. 5, pp. 646-674, 2011
2. L. Galluzzi, I. Vitale, J. M. Abrams et al., "Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012," Cell Death & Differentiation, vol. 19, no. 1, pp. 107-120, 2012
3. I. Vitale, L. Galluzzi, M. Castedo, and G. Kroemer, "Mitotic catastrophe: a mechanism for avoiding genomic instability," Nature Reviews Molecular Cell Biology, vol. 12, no. 6, pp. 385-392, 2011
4. G. Imreh, H. V. Norberg, S. Imreh, and B. Zhivotovsky, "Chromosomal breaks during mitotic catastrophe trigger H2AXATM-p53-mediated apoptosis," Journal of Cell Science, vol. 124, part 17, pp. 2951-2963, 2011
5. A. J. Holland and D. W. Cleveland, "Losing balance: the origin and impact of aneuploidy in cancer," The EMBO Reports, vol. 13, no. 6, pp. 501-514, 2012
6. D. J. Gordon, B. Resio, and D. Pellman, "Causes and consequences of aneuploidy in cancer," Nature Reviews Genetics, vol. 13, no. 3, pp. 189-203, 2012
7. T. Boveri, "Concerning the origin of malignant tumours by Theodor Boveri. Translated and annotated by Henry Harris," Journal of Cell Science, vol. 121, no. 1, pp. 1-84, 2008
8. F. Mitelman, B. Johansson, and F. E. Mertens, Mitelman Database of Chromosome Abberations and Gene Fusions in Cancer, Cancer Genome Anatomy Project, 2012, http://cgap. nci. nih . gov/Chromosomes/Mitelman
9. N. J. Quintyne, J. E. Reing, D. R. Hoffelder, S. M. Gollin, and W. S. Saunders, "Spindlemultipolarity is prevented by centrosomal clustering," Science, vol. 307, no. 5706, pp. 127-129, 2005
10. T. Fujiwara, M. Bandi, M. Nitta, E. V. Ivanova, R. T. Bronson, and D. Pellman, "Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells," Nature, vol. 437, no. 7061, pp. 1043-1047, 2005
11. D. M. Duelli, S. Hearn,M. P. Myers, and Y. Lazebnik, "A primate virus generates transformed human cells by fusion," The Journal of Cell Biology, vol. 171, no. 3, pp. 493-503, 2005
12. D. M. Duelli, H. M. Padilla-Nash, D. Berman, K. M. Murphy, T. Ried, and Y. Lazebnik, "A virus causes cancer by inducing massive chromosomal instability through cell fusion," Current Biology, vol. 17, no. 5, pp. 431-437, 2007
13. C. M. Caldwell, R. A. Green, and K. B. Kaplan, "APCmutations lead to cytokinetic failures in vitro and tetraploid genotypes in Min mice," Journal of Cell Biology, vol. 178, no. 7, pp. 1109-1120, 2007
14. A. J. Olaharski, R. Sotelo, G. Solorza-Luna et al., "Tetraploidy and chromosomal instability are early events during cervical carcinogenesis," Carcinogenesis, vol. 27,no. 2, pp. 337-343, 2006
15. L. Lv, T. Zhang, Q. Yi et al., "Tetraploid cells from cytokinesis failure induce aneuploidy and spontaneous transformation of mouse ovarian surface epithelial cells," Cell Cycle, vol. 11, no. 15, pp. 2864-2875, 2012
16. G. Högnäs, S. Tuomi, S. Veltel et al., "Cytokinesis failure due to derailed integrin traffic induces aneuploidy and oncogenic transformation in vitro and in vivo," Oncogene, vol. 31, no. 31, pp. 3597-3606, 2012
17. M. J. Daniels, Y. Wang, M. Lee, and A. R. Venkitaraman, "Abnormal cytokinesis in cells deficient in the breast cancer susceptibility protein BRCA2," Science, vol. 306, no. 5697, pp. 876-879, 2004
18. X. Yang, K. Yu, Y. Hao et al., "LATS1 tumour suppressor affects cytokinesis by inhibiting LIMK1," Nature Cell Biology, vol. 6, no. 7, pp. 609-617, 2004
19. A. J. Holland and D. W. Cleveland, "Boveri revisited: chromosomal instability, aneuploidy and tumorigenesis," Nature Reviews Molecular Cell Biology, vol. 10, no. 7, pp. 478-487, 2009
20. H. Hasle, I. H. Clemmensen, and M. Mikkelsen, "Risks of leukaemia and solid tumours in individuals with Down's syndrome," The Lancet, vol. 355, no. 9199, pp. 165-169, 2000
21. D. Satgé, D. Sommelet, A. Geneix, M. Nishi, P. Malet, and M. Vekemans, "A tumor profile in Down syndrome," American Journal of Medical Genetics, vol. 78, no. 3, pp. 207-216, 1998
22. A. D. Silk, L. M. Zasadil, A. J. Holland, B. Vitre, D. W. Cleveland, and B. A. Weaver, "Chromosome missegregation rate predicts whether aneuploidy will promote or suppress tumors," Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 44, pp. E4134-E4141, 2013
23. H. Hochegger, S. Takeda, and T. Hunt, "Cyclin-dependent kinases and cell-cycle transitions: does one fit all" Nature Reviews Molecular Cell Biology, vol. 9, no. 11, pp. 910-916, 2008
24. M. Malumbres and M. Barbacid, "Mammalian cyclin-dependent kinases," Trends in Biochemical Sciences, vol. 30, no. 11, pp. 630-641, 2005
25. C. Sacristan and G. J. Kops, "Joined at the hip: kinetochores, microtubules, and spindle assembly checkpoint signaling," Trends in Cell Biology, vol. 25, no. 1, pp. 21-28, 2015
26. M. Carmena, M. Wheelock, H. Funabiki, and W. C. Earnshaw, "The chromosomal passenger complex (CPC): from easy rider to the godfather of mitosis," Nature Reviews Molecular Cell Biology, vol. 13, no. 12, pp. 789-803, 2012
27. J. P. Fededa and D. W. Gerlich, "Molecular control of animal cell cytokinesis," Nature Cell Biology, vol. 14, no. 5, pp. 440-447, 2012
28. R. A. Green, E. Paluch, and K. Oegema, "Cytokinesis in animal cells," Annual Review of Cell and Developmental Biology, vol. 28, pp. 29-58, 2012
29. F. A. Barr and U. Gruneberg, "Cytokinesis: placing and making the final cut," Cell, vol. 131, no. 5, pp. 847-860, 2007
30. M. E. Bekier, R. Fischbach, J. Lee, and W. R. Taylor, "Length of mitotic arrest induced by microtubule-stabilizing drugs determines cell death after mitotic exit,"Molecular CancerTherapeutics, vol. 8, no. 6, pp. 1646-1654, 2009
31. K. E. Gascoigne and S. S. Taylor, "Cancer cells display profound intra-and interline variation following prolonged exposure to antimitotic drugs," Cancer Cell, vol. 14, no. 2, pp. 111-122, 2008
32. D. A. Brito and C. L. Rieder, "Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint," Current Biology, vol. 16,no. 12,pp. 1194-1200, 2006
33. C. H. Topham and S. S. Taylor, "Mitosis and apoptosis: how is the balance set" Current Opinion in Cell Biology, vol. 25, no. 6, pp. 780-785, 2013
34. M. A. Jordan and L. Wilson, "Microtubules as a target for anticancer drugs," Nature Reviews Cancer, vol. 4, no. 4, pp. 253-265, 2004
35. M. Malumbres and I. P. de Castro, "Aurora kinase A inhibitors: promising agents in antitumoral therapy," Expert Opinion on Therapeutic Targets, vol. 18, no. 12, pp. 1377-1393, 2014
36. J. R. Brown, K. K. Koretke, M. L. Birkeland, P. Sanseau, and D. R. Patrick, "Evolutionary relationships of Aurora kinases: implications for model organism studies and the development of anti-cancer drugs," BMC Evolutionary Biology, vol. 4, article 39, 2004
37. E. Manchado, M. Guillamot, and M. Malumbres, "Killing cells by targeting mitosis," Cell Death and Differentiation, vol. 19, no. 3, pp. 369-377, 2012
38. R. Jones, J. Vuky, T. Elliott et al., "Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer," Investigational New Drugs, vol. 31, no. 4, pp. 1001-1007, 2013
39. H. L. Gomez, M. Philco, P. Pimentel et al., "Phase I doseescalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer," AnticancerDrugs, vol. 23,no. 3, pp. 335-341, 2012
40. H. A. Burris III, S. F. Jones,D. D. Williams et al., "Aphase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors," Investigational New Drugs, vol. 29, no. 3, pp. 467-472, 2011
41. H. J. Khoury, G. Garcia-Manero, G. Borthakur et al., "A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, inpatientswithadvancedmyeloidleukemias," Cancer, vol. 118, no. 14, pp. 3556-3564, 2012
42. A. I. Marcus, U. Peters, S. L. Thomas et al., "Mitotic kinesin inhibitors induce mitotic arrest and cell death in taxol-resistant and-sensitive cancer cells,"The Journal of Biological Chemistry, vol. 280, no. 12, pp. 11569-11577, 2005
43. X. Qian, A. McDonald, H.-J. Zhou et al., "Discovery of the first potent and selective inhibitor of centromere-associated protein E: GSK923295," ACS Medicinal Chemistry Letters, vol. 1, no. 1, pp. 30-34, 2010
44. V. Chung, E. I. Heath, W. R. Schelman et al., "First-time-inhuman study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein e (CENP-E), in patients with refractory cancer," Cancer Chemotherapy and Pharmacology, vol. 69, no. 3, pp. 733-741, 2012
45. K. Strebhardt and A. Ullrich, "Targeting polo-like kinase 1 for cancer therapy," Nature Reviews Cancer, vol. 6, no. 4, pp. 321-330, 2006
46. J. Wagenblast, D. Hirth, L. Thron et al., "Effects of the polo-likekinase-1-inhibitor BI2536 in squamous cell carcinoma cell lines of the head and neck," Oncology Letters, vol. 4, no. 1, pp. 175-177, 2012
47. J. Wagenblast, D. Hirth, A. Eckardt et al., "Antitumoral effect of PLK-1-inhibitor BI2536 in combination with cisplatin and docetaxel in squamous cell carcinoma cell lines of the head and neck," Molecular and Clinical Oncology, vol. 1, no. 2, pp. 286-290, 2013
48. R. Colombo, M. Caldarelli, M. Mennecozzi et al., "Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase," Cancer Research, vol. 70, no. 24, pp. 10255-10264, 2010
49. R. B. Slee, B. R. Grimes, R. Bansal et al., "Selective inhibition of pancreatic ductal adenocarcinoma cell growth by themitotic MPS1 kinase inhibitor NMS-P715,"Molecular CancerTherapeutics, vol. 13, no. 2, pp. 307-315, 2014
50. M. Jemaà, L. Galluzzi, O. Kepp et al., "Characterization of novel MPS1 inhibitors with preclinical anticancer activity," Cell Death and Differentiation, vol. 20, no. 11, pp. 1532-1545, 2013
51. B. A. Tannous, M. Kerami, P. M. van der Stoop et al., "Effects of the selective MPS1 inhibitor MPS1-IN-3 on glioblastoma sensitivity to antimitotic drugs," Journal of the National Cancer Institute, vol. 105, no. 17, pp. 1322-1331, 2013
52. E. Manchado, M. Guillamot, G. de Cárcer et al., "Targeting mitotic exit leads to tumor regression in vivo: modulation by Cdk1, Mastl, and the PP2A/B55, phosphatase," Cancer Cell, vol. 18, no. 6, pp. 641-654, 2010
53. H.-C. Huang, J. Shi, J. D. Orth, and T. J. Mitchison, "Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly," Cancer Cell, vol. 16, no. 4, pp. 347-358, 2009
54. X. Zeng, F. Sigoillot, S. Gaur et al., "Pharmacologic inhibition of the anaphase-promoting complex induces a spindle checkpoint-dependent mitotic arrest in the absence of spindle damage," Cancer Cell, vol. 18, no. 4, pp. 382-395, 2010
55. V. Pannu, P. C. G. Rida, A. Ogden et al., "Induction of robust de novo centrosome amplification, high-grade spindle multipolarity and metaphase catastrophe: a novel chemotherapeutic approach," Cell Death and Disease, vol. 3, no. 7, article e346,2012
56. B. Rebacz, T. O. Larsen, M. H. Clausen et al., "Identification of griseofulvin as an inhibitor of centrosomal clustering in a phenotype-based screen," Cancer Research, vol. 67, no. 13, pp. 6342-6350, 2007
57. D. R. Wonsey and M. T. Follettie, "Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe," Cancer Research, vol. 65, no. 12, pp. 5181-5189, 2005
58. C. Vogel, C. Hager, and H. Bastians, "Mechanisms of mitotic cell death induced by chemotherapy-mediated G2 checkpoint abrogation," Cancer Research, vol. 67, no. 1, pp. 339-345, 2007
59. C. X. Ma, J. W. Janetka, and H. Piwnica-Worms, "Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics," Trends in Molecular Medicine, vol. 17, no. 2, pp. 88-96, 2011
60. Q. Wang, S. Fan, A. Eastman, P. J. Worland, E. A. Sausville, and P. M. O'Connor, "UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53," Journal of the National Cancer Institute, vol. 88, no. 14, pp. 956-965, 1996
61. C. X. Ma, S. Cai, S. Li et al., "Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models,"The Journal of Clinical Investigation, vol. 122, no. 4, pp. 1541-1552, 2012
62. I. Gojo, A. Perl,S. Luger et al., "Phase i studyofUCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome," Investigational New Drugs, vol. 31, no. 5, pp. 1217-1227, 2013
63. C. X. Ma, M. J. C. Ellis, G. R. Petroni et al., "A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer," Breast Cancer Research and Treatment, vol. 137, no. 2, pp. 483-492, 2013
64. C.-K. Lee, S. Wang,X. Huang, J. Ryder, and B. Liu, "HDACinhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells," Cancer Letters, vol. 296, no. 2, pp. 233-240, 2010
65. M. Cornago, C. Garcia-Alberich, N. Blasco-Angulo et al., "Histone deacetylase inhibitors promote glioma cell death by G2 checkpoint abrogation leading to mitotic catastrophe," Cell Death and Disease, vol. 5, no. 10, article e1435, 2014
66. E. J. Noh, D.-S. Lim, G. Jeong, and J.-S. Lee, "An HDAC inhibitor, trichostatin A, induces a delay at G2/M transition, slippage of spindle checkpoint, and cell death in a transcriptiondependentmanner," Biochemical and Biophysical ResearchCommunications, vol. 378, no. 3, pp. 326-331, 2009
67. D. T. Terrano, M. Upreti, and T. C. Chambers, "Cyclindependent kinase 1-mediated Bcl-xL/Bcl-2 phosphorylation acts as a functional link coupling mitotic arrest and apoptosis," Molecular and Cellular Biology, vol. 30, no. 3, pp. 640-656, 2010
68. M. E. Harley, L. A. Allan, H. S. Sanderson, and P. R. Clarke, "Phosphorylation of Mcl-1 by CDK1-cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest," The EMBO Journal, vol. 29, no. 14, pp. 2407-2420, 2010
69. J. Shi, Y. Zhou, H.-C. Huang, and T. J. Mitchison, "Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL," Cancer Research, vol. 71, no. 13, pp. 4518-4526, 2011
70. B. J. Tunquist, R. D. Woessner, and D. H. Walker, "Mcl-1 stability determines mitotic cell fate of human multiple myeloma tumor cells treated with the kinesin spindle protein inhibitor ARRY-520,"MolecularCancerTherapeutics, vol. 9, no. 7,pp. 2046-2056, 2010
71. N. Sakurikar, J. M. Eichhorn, S. E. Alford, and T. C. Chambers, "Identification of a mitotic death signature in cancer cell lines," Cancer Letters, vol. 343, no. 2, pp. 232-238, 2014
72. S. Mac Fhearraigh and M. M. Mc Gee, "Cyclin B1 interacts with the BH3-only protein Bim and mediates its phosphorylation by Cdk1 during mitosis," Cell Cycle, vol. 10, no. 22, pp. 3886-3896, 2011
73. R. Gilley, P. A. Lochhead, K. Balmanno, D. Oxley, J. Clark, and S. J. Cook, "CDK1, not ERK1/2 or ERK5, is required for mitotic phosphorylation of BIM," Cellular Signalling, vol. 24,no. 1, pp. 170-180, 2012
74. P. E. Czabotar, G. Lessene, A. Strasser, and J. M. Adams, "Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy," Nature Reviews Molecular Cell Biology, vol. 15, no. 1, pp. 49-63, 2014
75. C. R. Han, D. Y. Jun, J. Y. Lee, and Y. H. Kim, "Prometaphase arrest-dependent phosphorylation of Bcl-2 and Bim reduces the association of Bcl-2 with Bak or Bim, provoking Bak activation and mitochondrial apoptosis in nocodazole-treated Jurkat T cells," Apoptosis, vol. 19, no. 1, pp. 224-240, 2014
76. M. Upreti, E. N. Galitovskaya,R. Chuet al., "Identificationof the major phosphorylation site in Bcl-xL induced by microtubule inhibitors and analysis of its functional significance," The Journal of Biological Chemistry, vol. 283, no. 51, pp. 35517-35525, 2008
77. I. E. Wertz, S. Kusam, C. Lam et al., "Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7," Nature, vol. 471, no. 7336, pp. 110-114, 2011
78. O. Kutuk and A. Letai, "Displacement of Bim by Bmf and Puma rather than increase in Bim level mediates paclitaxel-induced apoptosis in breast cancer cells," Cell Death and Differentiation, vol. 17, no. 10, pp. 1624-1635, 2010
79. Z. Li, J. Zhang, Z. Liu, C.-W. Woo, and C. J. Thiele, "Downregulation of Bim by brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from paclitaxel but not etoposide or cisplatin-induced cell death," Cell Death and Differentiation, vol. 14, no. 2, pp. 318-326, 2007
80. R. Li, T. Moudgil, H. J. Ross, and H.-M. Hu, "Apoptosis of non-small-cell lung cancer cell lines after paclitaxel treatment involves the BH3-only proapoptotic protein Bim," Cell Death and Differentiation, vol. 12, no. 3, pp. 292-303, 2005
81. T. Kawabata, S. Tanimura, K. Asai, R. Kawasaki, Y. Matsumaru, and M. Kohno, "Up-regulation of pro-apoptotic protein bim and down-regulation of anti-apoptotic protein Mcl-1 cooperatively mediate enhanced tumor cell death induced by the combination of ERK kinase (MEK) inhibitor and microtubule inhibitor,"The Journal of Biological Chemistry, vol. 287, no. 13, pp. 10289-10300, 2012
82. A. V. Miller, M. A. Hicks, W. Nakajima, A. C. Richardson, J. J. Windle, and H. Harada, "Paclitaxel-induced apoptosis Is BAKdependent, but BAX and BIM-independent in breast tumor," PLoS ONE, vol. 8, no. 4,Article ID e60685, 2013
83. J. L. Andersen, C. E. Johnson, C. D. Freel et al., "Restraint of apoptosis during mitosis through interdomain phosphorylation of caspase-2," The EMBO Journal, vol. 28, no. 20, pp. 3216-3227, 2009
84. L. A. Allan and P. R. Clarke, "Phosphorylation of caspase-9 by CDK1/cyclin B1 protects mitotic cells against apoptosis," Molecular Cell, vol. 26, no. 2, pp. 301-310, 2007
85. Y. Matthess,M. Raab, M. Sanhaji, I. N. Lavrik, and K. Strebhardt, "Cdk1/Cyclin B1 controls fas-mediated apoptosis by regulating caspase-8 activity," Molecular and Cellular Biology, vol. 30, no. 24, pp. 5726-5740, 2010
86. K. Lee, A. E. Kenny, and C. L. Rieder, "Caspase activity is not required for the mitotic checkpoint or mitotic slippage in human cells," Molecular Biology of the Cell, vol. 22, no. 14, pp. 2470-2479, 2011
87. M. C. Wei, W.-X. Zong, E. H.-Y. Cheng et al., "Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death," Science, vol. 292, no. 5517, pp. 727-730, 2001
88. S. M. Kilbride and J. H. M. Prehn, "Central roles of apoptotic proteins in mitochondrial function," Oncogene, vol. 32, no. 22, pp. 2703-2711, 2013
89. S. P. Wheatley and I. A. McNeish, "Survivin: a protein with dual roles inmitosis and apoptosis," International Reviewof Cytology, vol. 247, pp. 35-88, 2005
90. D. S. O'Donovan, S. MacFhearraigh, J. Whitfield, L. B. Swigart, G. I. Evan, and M. M. Mc Gee, "Sequential Cdk1 and Plk1 phosphorylation of protein tyrosine phosphatase 1B promotes mitotic cell death.," Cell Death & Disease, vol. 4, article e468, 2013
91. A. B. Harbauer, M. Opalínska, C. Gerbeth et al., "Cell cycledependent regulation ofmitochondrial preprotein translocase," Science, vol. 346, no. 6213, pp. 1109-1113, 2014
92. Z. Wang, M. Fan, D. Candas et al., "Cyclin B1/Cdk1 coordinates mitochondrial respiration for cell-cycle G2/M progression," Developmental Cell, vol. 29, no. 2, pp. 217-232, 2014
93. M. K. Gardner, M. Zanic, and J. Howard, "Microtubule catastrophe and rescue," Current Opinion in Cell Biology, vol. 25, no. 1, pp. 14-22, 2013
94. F. Herzog, I. Primorac, P. Dube et al., "Structure of the anaphase-promoting complex/cyclosome interacting with a mitotic checkpoint complex," Science, vol. 323, no. 5920, pp. 1477-1481, 2009
95. A. Musacchio and E. D. Salmon, "The spindle-assembly checkpoint in space and time," Nature ReviewsMolecular Cell Biology, vol. 8, no. 5, pp. 379-393, 2007
96. A. Burgess, M. Rasouli, and S. Rogers, "Stressing mitosis to death," Frontiers in Oncology, vol. 4, article 140, 2014
97. A. E. Kelly and H. Funabiki, "Correcting aberrant kinetochore microtubule attachments: an Aurora B-centric view," Current Opinion in Cell Biology, vol. 21, no. 1, pp. 51-58, 2009
98. T. J. Maresca and E. D. Salmon, "Welcome to a new kind of tension: translating kinetochore mechanics into a waitanaphase signal," Journal of Cell Science, vol. 123, part 6, pp. 825-835, 2010
99. A. Janssen, G. J. P. L. Kops, and R. H. Medema, "Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 45, pp. 19108-19113, 2009
100. M. Malumbres, "Physiological relevance of cell cycle kinases," Physiological Reviews, vol. 91, no. 3, pp. 973-1007, 2011
101. M. Carmena and W. C. Earnshaw, "The cellular geography of aurora kinases," Nature Reviews Molecular Cell Biology, vol. 4, no. 11, pp. 842-854, 2003
102. S. M. A. Lens, E. E. Voest, and R. H. Medema, "Shared and separate functions of polo-like kinases and aurora kinases in cancer," Nature Reviews Cancer, vol. 10,no. 12,pp. 825-841, 2010
103. H. Zhou, J. Kuang, L. Zhong et al., "Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation," Nature Genetics, vol. 20, no. 2, pp. 189-193, 1998
104. F. Girdler, K. E. Gascoigne, P. A. Eyers et al., "Validating Aurora B as an anti-cancer drug target," Journal of Cell Science, vol. 119, no. 17, pp. 3664-3675, 2006
105. X. Liu and M. Winey, "The MPS1 family of protein kinases," Annual Review of Biochemistry, vol. 81, pp. 561-585, 2012
106. F. A. Barr, H. H. W. Silljé, and E. A. Nigg, "Polo-like kinases and the orchestration of cell division," Nature ReviewsMolecular Cell Biology, vol. 5, no. 6, pp. 429-440, 2004
107. M. Kimura, T. Yoshioka, M. Saio, Y. Banno, H. Nagaoka, and Y. Okano, "Mitotic catastrophe and cell death induced by depletion of centrosomal proteins," Cell Death and Disease, vol. 4, no. 4, article e603, 2013
108. T. Mayor, P. Meraldi, Y.-D. Stierhof, E. A. Nigg, and A. M. Fry, "Protein kinases in control of the centrosome cycle," FEBS Letters, vol. 452, no. 1-2, pp. 92-95, 1999
109. E. Doménech and M. Malumbres, "Mitosis-targeting therapies: a troubleshooting guide," CurrentOpinion in Pharmacology, vol. 13, no. 4, pp. 519-528, 2013
110. X. Yao,A. Abrieu, Y. Zheng, K. F. Sullivan, and D. W. Cleveland, "CENP-E forms a link between attachment of spindle microtubules to kinetochores and themitotic checkpoint," Nature Cell Biology, vol. 2, no. 8, pp. 484-491, 2000
111. B. A. A. Weaver, Z. Q. Bonday, F. R. Putkey, G. J. P. L. Kops, A. D. Silk, and D. W. Cleveland, "Centromere-associated protein-E is essential for the mammalian mitotic checkpoint to prevent aneuploidy due to single chromosome loss," Journal of Cell Biology, vol. 162, no. 4, pp. 551-563, 2003
112. U. S. Eggert, T. J. Mitchison, and C. M. Field, "Animal cytokinesis: from parts list to mechanisms," Annual Review of Biochemistry, vol. 75, pp. 543-566, 2006
113. H. Vakifahmetoglu, M. Olsson, and B. Zhivotovsky, "Death through a tragedy: mitotic catastrophe," Cell Death and Differentiation, vol. 15, no. 7, pp. 1153-1162, 2008
114. N. Bucher and C. D. Britten, "G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer," British Journal of Cancer, vol. 98, no. 3, pp. 523-528, 2008
115. R. Boutros, C. Dozier, and B. Ducommun, "The when and wheres of CDC25 phosphatases," Current Opinion in Cell Biology, vol. 18, no. 2, pp. 185-191, 2006
116. M. A. Mackey, X. F. Zhang, C. R. Hunt et al., "Uncoupling of Mphase kinase activation from the completion of S-phase by heat shock," Cancer Research, vol. 56, no. 8, pp. 1770-1774, 1996
117. T. A. Chan, H. Hermeking, C. Lengauer, K. W. Kinzler, and B. Vogelstein, "14-3-3 is required to prevent mitotic catastrophe after DNA damage," Nature, vol. 401, no. 6753, pp. 616-620, 1999
118. M. Castedo, J.-L. Perfettini, T. Roumier et al., "The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe," Oncogene, vol. 23, no. 25, pp. 4353-4361, 2004
119. H. Vakifahmetoglu, M. Olsson, C. Tamm, N. Heidari, S. Orrenius, and B. Zhivotovsky, "DNA damage induces two distinct modes of cell death in ovarian carcinomas," Cell Death and Differentiation, vol. 15, no. 3, pp. 555-566, 2008
120. H. Vakifahmetoglu, M. Olsson, S. Orrenius, and B. Zhivotovsky, "Functional connection between p53 and caspase-2 is essential for apoptosis induced by DNA damage," Oncogene, vol. 25, no. 41, pp. 5683-5692, 2006
121. A.-L. Salmela and M. J. Kallio, "Mitosis as an anti-cancer drug target," Chromosoma, vol. 122, no. 5, pp. 431-449, 2013
122. M. Kavallaris, "Microtubules and resistance to tubulin-binding agents," Nature Reviews Cancer, vol. 10, no. 3, pp. 194-204, 2010
123. Y. Huang, A. M. Ibrado, J. C. Reed et al., "Co-expression of severalmolecularmechanisms ofmultidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells," Leukemia, vol. 11, no. 2, pp. 253-257, 1997
124. D. Huszar, M.-E. Theoclitou, J. Skolnik, and R. Herbst, "Kinesin motor proteins as targets for cancer therapy," Cancer and Metastasis Reviews, vol. 28, no. 1-2, pp. 197-208, 2009
125. H. Dixon and C. J. Norbury, "Therapeutic exploitation of checkpoint defects in cancer cells lacking p53 function," Cell Cycle, vol. 1, no. 6, pp. 362-368, 2002
126. Y. Xiao, J. Ramiscal, K. Kowanetz et al., "Identification of preferred chemotherapeutics for combining with a CHK1 Inhibitor," Molecular Cancer Therapeutics, vol. 12, no. 11, pp. 2285-2295, 2013
127. P. C. de Witt Hamer, S. E. Mir, D. Noske, C. J. F. van Noorden, and T. Würdinger, "WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe," Clinical Cancer Research, vol. 17, no. 13, pp. 4200-4207, 2011
128. K.-S. Chan, C.-G. Koh, and H.-Y. Li, "Mitosis-targeted anticancer therapies: where they stand," Cell Death and Disease, vol. 3, no. 10, article e411, 2012
129. T. J. Mitchison, "The proliferation rate paradox in antimitotic chemotherapy," Molecular Biology of the Cell, vol. 23, no. 1, pp. 1-6, 2012
130. E. Komlodi-Pasztor, D. L. Sackett, and A. T. Fojo, "Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale," Clinical Cancer Research, vol. 18, no. 1, pp. 51-63, 2012
131. B. A. A. Weaver and D. W. Cleveland, "Decoding the links between mitosis, cancer, and chemotherapy: the mitotic checkpoint, adaptation, and cell death," Cancer Cell, vol. 8, no. 1, pp. 7-12, 2005
132. W. Tao, V. J. South, Y. Zhang et al., "Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage," Cancer Cell, vol. 8, no. 1, pp. 49-59, 2005
133. M. Chircop, S. Perera, A. Mariana et al., "Inhibition of dynamin by dynole 34-2 induces cell death following cytokinesis failure in cancer cells,"Molecular CancerTherapeutics, vol. 10,no. 9, pp. 1553-1562, 2011
134. J. D. Kessler, K. T. Kahle, T. Sun et al., "A SUMOylationdependent transcriptional subprogram is required for Mycdriven tumorigenesis," Science, vol. 335, no. 6066, pp. 348-353, 2012
135. D. Annibali, J. R. Whitfield, E. Favuzzi et al., "Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis," Nature Communications, vol. 5, article 4632, 2014
136. L. Lu, H. Han, Y. Tian et al., "Aurora kinase A mediates c-Myc's oncogenic effects in hepatocellular carcinoma,"Molecular Carcinogenesis, 2014
137. W. C. Gustafson, J. G. Meyerowitz, E. A. Nekritz et al., "Drugging MYCN through an allosteric transition in Aurora kinase A," Cancer Cell, vol. 26, no. 3, pp. 414-427, 2014.